All In Biotech

Drug Trial Radar · NCT03157635

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Nov 14, 2016

Primary completion

Aug 13, 2026

Study completion Aug 13, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
May 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of crovalimab will be evaluated in participants with paroxysmal nocturnal hemoglobinuria (PNH) in parts 2, 3, 4, and OLE of the study. Efficacy of crovalimab will be evaluated in Parts 2, 3, and 4.

Conditions

  • Paroxysmal Hemoglobinuria, Nocturnal

Interventions

  • CrovalimabDrug

    Crovalimab will be administered as per schedule described in individual arm.

  • PlaceboDrug

    Placebo will be administered as per schedule described in Part 1 placebo arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Participants With Dose-Limiting Events (DLEs)Time frame: Baseline up to approximately 3 months
  2. Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to approximately 3 months
  3. Part 2: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
  4. Part 3: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
  5. Part 4: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
  6. Part 2: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)Time frame: Baseline up to Day 224
  7. Part 3: Terminal Complement Activity as Assessed by Ex Vivo Liposome Lysis in Serum Using the LIATime frame: Baseline up to Day 224
  8. Part 4: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)Time frame: Baseline up to Day 224
  9. OLE: Percentage of Participants With AEs and SAEsTime frame: OLE: Week 21 up to Week 567

Locations

15 sites in 7 countries. Site status is shown where the registry gives one.

  • Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis

    Paris, France

  • Uniklinik RWTH Aachen

    Aachen, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Semmelweis Egyetem, 1. Szamu Belgyogyaszati Klinika, Diabetologia

    Budapest, Hungary

  • Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology

    Kaposvár, Hungary

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, Italy

  • Tohoku University Hospital

    Miyagi, Japan

  • Osaka University Hospital

    Osaka, Japan

  • NTT Medical Center Tokyo

    Tokyo, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • University of Tsukuba Hospital

    Tsukuba, Japan

  • Pra International Group B.V

    Groningen, Netherlands

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Seoul National University Hosp

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.